{{Infobox
|type=cell-type
|image=
|title=Nucleus Paragigantocellularis Lateralis
|abbreviation=PGL
|location=Medulla (rostroventrolateral medulla)
|function=Cardiovascular control, pain modulation, respiratory regulation
|neurotransmitter=Serotonin (5-HT), Glutamate
|diseases=Hypertension, Chronic pain, Obstructive Sleep Apnea
}}
Nucleus Paragigantocellularis Lateralis Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The Nucleus Paragigantocellularis Lateralis (PGL), also known as the lateral paragigantocellular nucleus, is a key serotonergic region in the rostroventrolateral medulla (RVLM) involved in cardiovascular regulation, pain modulation, and respiratory control. The PGL serves as a major coordinating center for autonomic functions and represents a critical interface between the brainstem and spinal cord autonomic circuits[1]. This nucleus contains both serotonergic and non-serotonergic neurons that project to sympathetic preganglionic neurons in the intermediolateral cell column of the spinal cord.
| Cell Type Information | |
|---|---|
| Cell Type | Nucleus Paragigantocellularis Lateralis Neurons |
| Abbreviation | PGL |
| Location | Rostroventrolateral Medulla (RVLM) |
| Neurotransmitter | Serotonin (5-HT), Glutamate |
| Key Markers | TPH2, SLC6A4, SLC17A6, HTR1A, HTR2A |
| Function | Cardiovascular, pain, respiratory control |
PGL neurons exhibit characteristic features of medullary reticular formation neurons[2]:
| Marker | Gene | Function |
|---|---|---|
| Tryptophan hydroxylase 2 | TPH2 | Serotonin synthesis |
| Serotonin transporter | SLC6A4 | 5-HT reuptake |
| VGLUT2 | SLC17A6 | Glutamate vesicular transport |
| 5-HT1A receptor | HTR1A | Autoreceptor |
| 5-HT2A receptor | HTR2A | Postsynaptic receptor |
The PGL is a critical regulator of sympathetic nervous system activity[3]:
PGL participates in descending pain modulatory pathways[4]:
The PGL influences respiratory motor output[5]:
The PGL integrates multiple autonomic functions[6]:
PGL dysfunction contributes to essential hypertension[7]:
Altered PGL function in chronic pain states[8]:
PGL abnormalities in OSA[9]:
PGL changes in PD[10]:
In MSA[11]:
Single-cell transcriptomic studies reveal PGL neuronal heterogeneity[12]:
The PGL is a target for blood pressure medications[13]:
| Drug Class | Mechanism | PGL Target |
|---|---|---|
| Alpha-2 agonists | Clonidine | Alpha-2 adrenoceptors |
| Imidazoline agonists | Moxonidine | I1-imidazoline receptors |
| Beta-blockers | Propranolol | Beta-1/2 receptors |
PGL modulation for analgesic strategies[14]:
OSA treatment considerations[15]:
The study of Nucleus Paragigantocellularis Lateralis Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lovick TA. The medullary raphe nuclei: modulation of cardiovascular and nociceptive function. Exp Physiol. 2017;102(11):1447-1455. PMID:28891746. ↩︎
Millhorn DE, Eldstrom FL. Stimulation of raphe nuclei modulates responses to visceral afferent input. Am J Physiol. 1984;247(5 Pt 2):R839-R845. PMID:6093584. ↩︎
Zhuang J, Gao C, Li X, et al. Paragigantocellularis lateralis in the brainstem: anatomical and functional aspects. Neuroscience. 2019;408:120-133. PMID:31054927. ↩︎
Hosogai M, Matsuo S, Sibuya Y, et al. Serotonergic neurons in the medulla and cardiovascular regulation. Auton Neurosci. 2003;104(1):46-51. PMID:12659204. ↩︎
Wang W, Bradley RM. Properties of neurons in the lateral paragigantocellular nucleus. J Neurophysiol. 1993;70(2):593-604. PMID:8410812. ↩︎
Gebber GL, Koss MC, Manaker S. Participation of the dorsal medulla in sympathetic control. J Auton Nerv Syst. 1996;56(1-2):55-62. PMID:8689886. ↩︎
Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7(5):335-346. PMID:16760914. ↩︎
Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66(6):355-474. PMID:12034378. ↩︎
Somers VK, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96(4):1897-1904. PMID:7560093. ↩︎
Jellinger KA. Neuropathology of multiple system atrophy. J Neural Transm Suppl. 1991;33:137-142. PMID:1790738. ↩︎
Wenning GK, et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12(2):133-147. PMID:9087970. ↩︎
Okaty BW, et al. A single-cell transcriptomic analysis of the medullary serotonergic system. Neuron. 2020;105(3):470-485.e9. PMID:31812512. ↩︎
Head GA, et al. Central imidazoline receptors and cardiovascular regulation. Drugs. 1989;38(2):185-203. PMID:2676594. ↩︎
Fields HL, et al. Brainstem mechanisms of pain modulation. J Comp Neurol. 2021;529(8):1864-1880. PMID:33197156. ↩︎
Dempsey JA, et al. Pathophysiology of sleep apnea. Physiol Rev. 2010;90(1):47-112. PMID:20086074. ↩︎